Figure 3.
Somatic alteration burden and HLA zygosity are not associated with clinical outcome with PD-1 blockade. (a-d). Measures of sample-wide somatic burden, including number of (a) tumor mutations, (b) neoantigen load, (c) frameshift indels and (d) weighted genome integrity index (wGII) were not associated with clinical benefit with PD-1 blockade (two-sided Wilcoxon rank-sum test). Boxplot hinges represent 25th to 75th percentiles, central lines represent the medians, the whiskers extend to highest and lowest values no greater than 1.5× interquartile range and the dots indicate outliers; the violin component refers to the kernel probability density and encompasses all cells. (e) HLA zygosity was not associated with progression-free or overall survival (two-sided log-rank test).